Most active New York Stock Exchange-traded stocks
AP - Wed Oct 15, 5:08PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KMI: 35.29 (+0.79), GE: 24.28 (+0.18), F: 13.62 (-0.16), AA: 14.50 (+0.21), JPM: 55.53 (-2.46), AMD: 2.61 (-0.01), PFE: 28.19 (-0.27), C: 49.68 (-1.79), BAC: 15.76 (-0.76), WFC: 47.85 (-0.98), KEY: 12.14 (-0.75), TWTR: 49.99 (+1.41)
Final Glance: Pharmaceuticals companies
AP - Wed Oct 15, 5:08PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 98.21 (+1.20), BAX: 68.34 (-0.52), PFE: 28.19 (-0.27), BMY: 48.96 (+0.04)
3 Small-Cap Biotech Stocks to Buy if the Market Crashes
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 1:38PM CDT
The Russell 2000 small-cap stock index is the most widely used proxy for small-cap stocks and the exchange traded fund that tracks that index has tumbled 11.6% this year. That's a frightening drop, but it's been proven time and time again that...
JNJ: 98.21 (+1.20), INSY: 37.28 (+2.29), PTLA: 25.82 (+0.21), PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), OPHT: 40.75 (+2.59), IWM: 106.60 (+1.06), BMY: 48.96 (+0.04), REGN: 334.75 (+6.68)
Midday Glance: Pharmaceuticals companies
AP - Wed Oct 15, 12:17PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 98.21 (+1.20), BAX: 68.34 (-0.52), PFE: 28.19 (-0.27), BMY: 48.96 (+0.04)
Shire Falls, AbbVie Questioned On Buyout Backtrack
at Investor's Business Daily - Wed Oct 15, 12:11PM CDT
Shares of specialty drugmaker Shire plummeted 23% on the stock market today after word got out late Tuesday that big pharma AbbVie is reconsidering its $55 billion buyout of the company. Shire (SHPG) confirmed the reports Wednesday morning with a...
ABT: 40.01 (-1.05), AZN: 68.41 (-1.40), PFE: 28.19 (-0.27), SHPG: 170.49 (-74.08), SLXP: 132.42 (-1.16), MYL: 47.38 (+0.56), ABBV: 54.63 (+0.50)
Pfizer (PFE) Breaks Through Support at $28.31
Comtex SmarTrend(R) - Wed Oct 15, 10:40AM CDT
Shares of Pfizer (NYSE
PFE: 28.19 (-0.27)
Early Glance: Pharmaceuticals companies
AP - Wed Oct 15, 9:47AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 98.21 (+1.20), BAX: 68.34 (-0.52), PFE: 28.19 (-0.27), BMY: 48.96 (+0.04)
AbbVie Backs Away From Shire Takeover After Tax Changes
at The Street - Wed Oct 15, 9:27AM CDT
The Dublin target insists the deal should go ahead and notes that it's in line for a $1.635 billion breakup fee if it collapses.
MDT: 62.25 (-1.26), SHPG: 170.49 (-74.08), PFE: 28.19 (-0.27), COV: 85.86 (-6.50), ABBV: 54.63 (+0.50)
Johnson & Johnson and Bristol-Myers Squibb’s New Collaboration Just the Tip of the Iceberg
Brian Orelli, The Motley Fool - Motley Fool - Wed Oct 15, 7:45AM CDT
If one drug is good, two drugs must be better. That seems to be what Johnson & Johnson and Bristol-Myers Squibb are thinking with the clinical trial collaboration agreement they entered to test Johnson & Johnson's Imbruvica with...
JNJ: 98.21 (+1.20), PCYC: 108.03 (+4.24), PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), BMY: 48.96 (+0.04), NVS: 86.22 (-0.65)
FDA Sends Mixed Message On Safety of Pfizer inc.'s Chantix
Brian Orelli, The Motley Fool - Motley Fool - Wed Oct 15, 7:35AM CDT
Sales of Pfizer 's Chantix were knocked down a few years ago when the Food and Drug Administration slapped a black box warning on the smoking cessation drug after reports of patients experiencing neuropsychiatric events, including thoughts of...
PFE: 28.19 (-0.27), GSK: 43.13 (-0.55)
European Stocks Fall on Continued Worries Over Eurozone Economy
at The Street - Wed Oct 15, 4:58AM CDT
European stocks fall on Wednesday, failing to take their cue from a largely positive day in Asia as investors continue to worry about the outlook for the eurozone economy.
SHPG: 170.49 (-74.08), QCOM: 71.20 (-0.66), PFE: 28.19 (-0.27), MCHP: 37.73 (-0.48), AZN: 68.41 (-1.40), ABBV: 54.63 (+0.50)
Global Partial Seizure Clinical Trials Review, H2, 2014
M2 - Wed Oct 15, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8gwn27/partial_seizure) has announced the addition of the "Partial Seizure Global Clinical Trials Review, H2, 2014" report to their offering. Partial Seizure Global Clinical Trials Review, H2, 2014 provides data on the Partial Seizure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Partial Seizure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Partial Seizure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Partial Seizure Therapeutics Clinical Trials - UCB S.A. - Pfizer Inc. - Eisai Co., Ltd. - Novartis AG - Johnson & Johnson - GlaxoSmithKline plc - Bial - Portela & Ca, S.A. - SK Holdings Co., Ltd. - Upsher-Smith Laboratories, Inc. - Abbott Laboratories - National Institute of Neurological Disorders and Stroke - Emory University - Oregon Health & Science University - Kyoto University - National Center for Complementary and Alternative Medicine - Hadassah Medical Organization - University of Pennsylvania - Lawson Health Research Institute - Massachusetts General Hospital - University of California, Davis For more information visit http://www.researchandmarkets.com/research/8g...al_seizure
JNJ: 98.21 (+1.20), ABT: 40.01 (-1.05), PFE: 28.19 (-0.27), GSK: 43.13 (-0.55), NVS: 86.22 (-0.65)
Market Maker Surveillance Report. PFE, C, NOK, BAC, MSFT, GRPN, Bullishly Biased Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Pfizer Inc (NYSE
C: 49.68 (-1.79), PFE: 28.19 (-0.27), BAC: 15.76 (-0.76), GRPN: 6.27 (+0.34), MSFT: 43.22 (-0.51), NOK: 7.77 (-0.19)
FDA: little evidence to drop Chantix boxed warning
By MATTHEW PERRONE - AP - Tue Oct 14, 5:57PM CDT
WASHINGTON (AP) — Federal regulators say Pfizer has provided low-quality evidence to support its request to remove a bold-letter warning from its anti-smoking drug Chantix about suicidal behavior.
PFE: 28.19 (-0.27)
Pfizer's Breast Cancer Candidate Gets Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 5:00PM CDT
Pfizer Inc.'s (PFE) palbociclib is under the FDA's priority review for the first-line treatment in combination with Femara for ER+, HER2 advanced breast cancer.
AZN: 68.41 (-1.40), PFE: 28.19 (-0.27), LGND: 46.28 (+0.45), NVS: 86.22 (-0.65)
A Quick Look at Pfizer Inc.'s Drug Development Pipeline
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 14, 1:15PM CDT
Source: StockMonkeys.com via Flickr The stock market offers plenty of industries for investors to choose from, but when it comes to looking deep into the future and basing a company's valuation more on promise than on its present-day products,...
PFE: 28.19 (-0.27), NVS: 86.22 (-0.65)
Can Dividend Stock GlaxoSmithKline plc Bounce Back?
George Budwell, The Motley Fool - Motley Fool - Tue Oct 14, 12:09PM CDT
The pharmaceutical industry has a bad rep when it comes to corruption in general and bribery in particular. For example, French drugmaker Sanofi recently fessed up to U.S. authorities about an illegal payment scheme to doctors in East Africa and...
PFE: 28.19 (-0.27), MRK: 54.73 (-1.60), AMGN: 130.90 (-1.30), LLY: 62.87 (-0.27), GSK: 43.13 (-0.55), BMY: 48.96 (+0.04), SNY: 51.50 (-0.75), NVS: 86.22 (-0.65)
Where Will Celgene Corporation Stock Be a Year From Now?
Motley Fool Staff - Motley Fool - Tue Oct 14, 11:20AM CDT
Source: Celgene. The markets have gotten a little panicky lately, so last week we asked some of our top analysts to tell us what they think are the best companies to buy in a time of tumbling ticker tape . One pick was Celgene , a biotech...
JNJ: 98.21 (+1.20), PFE: 28.19 (-0.27), AMGN: 130.90 (-1.30), CELG: 86.55 (+0.07)